The prevalence, low-density lipoprotein cholesterol levels, and treatment of patients at very high risk of cardiovascular events in the United Kingdom: a cross-sectional study

References

• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 2016;23:NP1-NP96
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010;304:1350-7
   PubMed Web of Science ®Google Scholar
• Krempf M, Parhofer KG, Steg PG, et al. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol 2010;105:667-71
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889-934
   PubMed Web of Science ®Google Scholar
• Selwaness M, Bos D, van den Bouwhuijsen Q, et al. Carotid atherosclerotic plaque characteristics on magnetic resonance imaging relate with history of stroke and coronary heart disease. Stroke 2016;47:1542-7
   PubMed Web of Science ®Google Scholar
• Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 2017;70:1-25
   PubMed Web of Science ®Google Scholar
• Wilkins E, Wilson L, Wickeamasinghe K, et al. European cardiovascular disease statistics 2017. Brussels: European Heart Network; 2017. Available at: http://www.ehnheart.org/cvd-statistics.html [Last accessed 29 November 2017]
   Google Scholar
• Ballantyne C, Arroll B, Shepherd J. Lipids and CVD management: towards a global consensus. Eur Heart J 2005;26:2224-31
   PubMed Web of Science ®Google Scholar
• JBS3 Board. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014;100(Suppl 2):ii1-ii67
   PubMed Web of Science ®Google Scholar
• Adhyaru BB, Jacobson TA. Role of non-statins, LDL-C thresholds, and special population considerations: a look at the updated 2016 ACC consensus committee recommendations. Curr Atheroscler Rep 2017;19:29
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). NICE guideline: cardiovascular disease: risk assessment and reduction, including lipid modification (CG181). NICE; 2014. Available at: https://www.nice.org.uk/guidance/cg181/resources/cardiovascular-disease-risk-assessment-and-reduction-including-lipid-modification-35109807660997 [Last accessed 29 November 2017]
   Google Scholar
• Krahenbuhl S, Pavik-Mezzour I, von Eckardstein A. Unmet needs in LDL-C lowering: when statins won’t do! Drugs 2016;76:1175-90
   PubMed Web of Science ®Google Scholar
• Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
   PubMed Web of Science ®Google Scholar
• Danese MD, Gleeson M, Kutikova L, et al. Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. BMJ Open 2017;7:e013851
   PubMed Web of Science ®Google Scholar
• R. Comprehensive R Archive Network. 2017. Available at: http://cran.r-project.org [Last accessed 29 November 2017]
   Google Scholar
• Jaworski K, Jankowski P, Kosior DA. PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade. Arch Med Sci 2017;13:914-29
   PubMed Web of Science ®Google Scholar
• Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014;311:1870-82
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22
   PubMed Web of Science ®Google Scholar
• Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol 2017;2:598-607
   PubMed Web of Science ®Google Scholar
• Toth PP, Worthy G, Gandra SR, et al. Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia. J Am Heart Assoc 2017;6:e005367
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016;23:636-48
   PubMed Web of Science ®Google Scholar
• Reiner Z, De Backer G, Fras Z, et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries—Findings from the EUROASPIRE IV survey. Atherosclerosis 2016;246:243-50
   PubMed Web of Science ®Google Scholar
• Bhatnagar P, Wickramasinghe K, Williams J, et al. The epidemiology of cardiovascular disease in the UK 2014. Heart 2015;101:1182-9
   PubMed Web of Science ®Google Scholar
• Agabiti RE, Salvetti M. Management of hypercholesterolemia, appropriateness of therapeutic approaches and new drugs in patients with high cardiovascular risk. High Blood Press Cardiovasc Prev 2016;23:217-30
   PubMed Web of Science ®Google Scholar